ASHP COVID-19 VACCINE PLANNING TOOL for Pharmacists and Pharmacies



Welcome to the COVID-19 Vaccine Assessment Tool for Pharmacies. This tool incorporates the <u>ASHP Principles for COVID-19 Vaccine Distribution</u>, <u>Allocation</u>, <u>and Mass Immunization</u>. It is intended to assist in COVID-19 vaccine(s) planning efforts in hospitals, health systems, ambulatory care clinics, and other departments of pharmacy and to foster pharmacist and pharmacy staff involvement in COVID-19 vaccine preparedness at institutional and community levels. It is applicable in any pharmacy practice setting where a pharmacist and/or pharmacy technician is leading or assisting in the distribution, allocation, and administration of the COVID-19 vaccine(s). This tool is not intended to cover all aspects of vaccine distribution</u>, allocation, and mass immunizations, but is intended to be useful in identifying gaps and

The tool is divided into the following planning categories:

vulnerabilities in readiness and preparedness for the COVID-19 vaccine.

- Integration with Institutional Planning
- » Vaccine Supply and Distribution
- » Infrastructure
- » Personnel
- » Patient Care
- » Vaccine Safety Monitoring and Surveillance
- » Legislative and Regulatory Controls

The information contained in this self-assessment tool is emerging and rapidly evolving because of ongoing research and is subject to the professional judgment and interpretation of the practitioner. ASHP has made reasonable efforts to ensure the accuracy and appropriateness of the information presented. However, any reader of this information is advised that ASHP is not responsible for the continued currency of the information, for any errors or omissions, and/or for any consequences arising from the use of the information in the self-assessment tool. Any user of the self-assessment tool is cautioned that ASHP makes no representation, guarantee, or warranty, express or implied, as to the accuracy and appropriateness of the information contained in it, and will bear no responsibility or liability for the results or consequences of its use.



	YES	IN PROGRESS	NO	INTEGRATION WITH INSTITUTIONAL PLANNING	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
1				Does the pharmacy have a COVID-19 vaccine plan that includes vaccine and ancillary supply and distribution, infrastructure, personnel, legislative and regulatory controls?		
2				Has the pharmacy identified an individual(s) who will maintain, update, and implement the vaccine plan?		
3				Has the pharmacy COVID-19 vaccine plan been integrated into the COVID-19 pandemic preparedness plan?		ASHP COVID-19 Pandemic Assessment Tool
4				Has the pharmacy participated in planning efforts to deliver vaccines at their main site(s) and all other designated alternate care site(s)?		
5				Has the pharmacy participated in COVID-19 vaccine business plans that include tracking of labor, supplies, and expenses required for the plan implementation?		
6				Has the pharmacy designated a staff member to coordinate education, training needs, and programs to implement the COVID-19 vaccine plan?		



7				Has the pharmacy participated in the development of a prioritization process for ordering, dispensing, administering and monitoring the COVID-19 vaccine(s), with considerations of local, state, and federal guidance?		
	YES	IN PROGRESS	NO	VACCINE SUPPLY AND DISTRIBUTION	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
8				Have pharmacy personnel reviewed CDC and state and local health department recommendations and guidance for the use, availability, access, allocation and distribution of COVID-19 vaccine(s) to ensure a successful and well-coordinated mass vaccine administration campaign?		COVID-19 Vaccine Program Planning Assumptions for Jurisdictions
9				Has the pharmacy collaborated with the hospital, health system, and/or clinic to develop COVID-19 vaccine use plan and priorities for patients, staff, families of staff, and special populations?		
10				Does the COVID-19 vaccine plan outline who will receive and distribute the vaccine, such as healthcare providers, health departments, health systems, pharmacies, and the Vaccines for Children Program?		CDC Vaccines for Children Program



11				Has the pharmacy participated in efforts to estimate the quantities of vaccines, ancillary supplies (syringes, swabs, sharps, containers), and personal protective equipment that would be needed to implement the COVID-19 vaccine plan?		
12				Has the pharmacy participated in efforts to ensure supply of and access to vaccines, other vaccinerelated materials and equipment, and personal protective equipment that would be needed to implement the COVID-19 vaccine plan?		
13				Has the pharmacy participated in plans to manage external (i.e., community-wide) demand for COVID-19 vaccines?		
14				Has the pharmacy developed plans to monitor supply availability of vaccine(s) and ancillary supply to identify and mitigate shortages?		
	YES	IN PROGRESS	NO	INFRASTRUCTURE	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
15				Has the pharmacy participated in COVID-19 vaccine plans to identify provider-based locations to administer the COVID-19 vaccines, such as clinics (family medicine and specialty), hospitals, care facilities, and pharmacies?		

4



16				Has the pharmacy participated in COVID-19 vaccine plans to identify mass vaccine administration locations to administer the COVID-19 vaccine, such as schools, nursing homes, prisons, churches, and sport complexes?		
17				Has the pharmacy ensured appropriate storage and handling of COVID-19 vaccines, such as proper cold chain storage units, storage capacity, and temperature controls?		Early COVID-19 Vaccination Program Action Items for Jurisdictions
18				Has the pharmacy ensured appropriate monitoring controls such as security, remote temperature monitoring, alarm notifications, and emergency response for transport and relocation of COVID-19 vaccines to help prevent the vaccine from being compromised and to assure the maximum vaccine shelf-life?		
	YES	IN PROGRESS	NO	PERSONNEL	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
19				Has the pharmacy staff received training and demonstrated competence in the transport, handling, and storage of temperature-sensitive formulations of COVID-19 vaccine(s)?		Early COVID-19 Vaccination Program Action Items for Jurisdictions



20		Has the pharmacy staff been provided with evidence-based information related to the safe and effective use of COVID-19 vaccines?	
21		Has the pharmacy participated in the development of mass vaccine administration workflow procedures and identified the staff needed to perform these procedures?	
22		Has the pharmacy participated in vaccine plan strategies to address expanding capacity for a mass vaccine administration effort, including the use of alternative personnel resources, such as clinical nurses, medical assistants, pharmacy technicians, community health and school nurses, clinical learners (e.g., medical, pharmacy, and nursing), state/federal healthcare professionals (e.g., U.S. National Guard, military, Public Health Service), and/or retired healthcare professionals to ensure uninterrupted implementation of the vaccine plan?	
23		Has the pharmacy included a section in the pharmacy plan that addresses expediting the identification and training of immunizing staff?	

6



24				In the vaccine plan, has the pharmacy included a section that assigns responsibility for conducting a regular assessment of staffing status and needs regarding vaccines during a COVID-19 pandemic?		
25				Has the pharmacy implemented personal protective equipment requirements for staff, along with implementing policies and procedures to minimize exposure to COVID-19 between patients and staff?		
26				Has the pharmacy participated in policy and procedure planning related to implementation of employee vaccines, including procedures for employee refusal of the vaccine(s)?		
	YES	IN PROGRESS	NO	PATIENT CARE	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
27				Has the pharmacy educated staff members and other healthcare professionals involved with the hospital's COVID-19 vaccine plan, about the pharmacy's role, such as relevant personnel policies, and operational changes to ensure appropriate patient care?		



28		Has the pharmacy collaborated with hospital, health-system and/or ambulatory care clinic staff members to design, develop, and provide evidence-based information for patients that is culturally and health-literacy sensitive to ensure proper patient education about the COVID-19 vaccine?	
29		Has the pharmacy participated in COVID-19 vaccine plans for communication with patients and their family members about the COVID-19 vaccine?	
30		Has the pharmacy identified communication needs and methods of communication that are appropriate for individuals with visual, hearing, or other disabilities or limited English proficiency?	
31		Does the vaccine plan outline resources needed for patients to address potential patient fear/anxiety and improve confidence related to COVID-19 vaccine?	
32		Has the pharmacy participated in policy and procedure planning related to implementation of patient vaccines including patient refusal of the vaccines?	



33				Does the vaccine plan identify priority populations for targeted COVID-19 vaccine during the time that supply is constrained (e.g., frontline healthcare workers, critical infrastructure workers, elderly, those with co-morbidities, and other vulnerable populations)?		Cybersecurity & Infrastructure Security Agency (CISA) Identifying Critical Infrastructure During COVID-19
34				Does the vaccine plan address the needs of special populations (e.g., pregnancy and immunocompromised patients)?		
35				Does the vaccine plan outline procedures for anaphylaxis monitoring, treatment, and support?		
	YES	IN PROGRESS	NO	VACCINE SAFETY MONITORING AND SURVEILLANCE	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
36				Has the pharmacy participated in the development of a process to ensure utilization of an immunization information system (IIS) or immunization registry to collect data on which product (product, lot number, expiration) was administered and to ensure that multiple doses are administered and administered at the right interval?		CDC Immunization Information Systems (IIS)



37				As part of post-marketing and ongoing safety surveillance, has the pharmacy participated in a plan to identify, track, and report COVID-19 vaccinerelated adverse events through the Vaccine Adverse Event Reporting System and Institute for Safe Medication Practices Medication Error Reporting Program?		VAERS Institute for Safe Medication Practices Medication Error Reporting Program
38				Does the vaccine plan include quality monitoring and performance improvement policies and procedures?		
	YES	IN PROGRESS	NO	LEGISLATIVE AND REGULATORY CONTROLS	ASSESSMENT COMMENTS	ADDITIONAL RESOURCES
39				Has the pharmacy determined the actions that federal and state public health agencies have taken to authorize, suspend, or modify scope of practice requirements?		
40				Has the pharmacy addressed IIS or immunization registry delegates and permissions?		CDC Immunization Information Systems (IIS)
41				Is the pharmacy abiding by federal and state authorizations, age exemptions, and reporting requirements?		
42				Does the vaccine plan address reimbursement policies (administration and facility fees) including quality measure reporting?		



RESOURCE LINKS

- 1. CDC COVID-19 Hospital Preparedness Assessment Tool
- 2. CDC Vaccine Administration
- 3. CDC Vaccine Storage and Handling Toolkit
- 4. CDC Patient Education
- 5. Immunization Action Coalition Vaccine Storage and Handling
- 6. ASHP COVID-19 Pandemic Assessment Tool for Health-System Pharmacy Departments
- 7. COVID-19 Healthcare Planning Checklist
- 8. COVID-19 Vaccination Program Planning Assumptions for Jurisdictions
- 9. Early COVID-19 Vaccination Program Action Items for Jurisdictions
- 10. <u>Cybersecurity & Infrastructure Security Agency (CISA) Identifying Critical Infrastructure During COVID-19</u>
- 11. HHS Strategy for Distributing a COVID-19 Vaccine
- 12. CDC COVID-19 Vaccination Program Interim Playbook

